Objective: To describe the methodological challenges and decisions made in developing a multisite, controlled study of risperidone in children and adolescents with autism.
Introduction
Autistic disorder is a chronic condition of early childhood onset characterized by profound impairments in social relatedness, communication skills, and restricted patterns of The study was divided into three phases designed to evaluate the short-and long-term safety and efficacy of risperidone in children and adolescents with autistic disorder. Phase 1 was an 8-week, double-blind, randomized, parallel-groups comparison of risperidone and placebo. Subjects assigned to placebo who did not improve were offered an 8-week open-label trial of risperidone. Phase 2 consisted of a 4-month open-label treatment with risperidone for patients who showed improvement in the 8-week acute trial. The subsequent phase 3 was a randomized, double-blind, placebo-controlled discontinuation study (see Fig. 1 ). The target symptoms included tantrums, aggression, SIB, agitation, screaming, emotional rigidity, and repetitive behavior as measured by the Irritability subscale of the Aberrant Behavior Checklist completed by the parent or primary caretaker (Aman and Singh 1986; Aman et al. 1985; Mashburn and Arman 1992) . This subscale was selected because of its favorable psychometric properties (Mashburn and Aman 1992) , and it contains the behaviors of interest. To avoid overreliance on an informant-based measure, the study also included clinician and laboratory measures as secondary outcomes (for a detailed description of assessment measures used in the study, see Arnold et al. 2000) . The rationale for choosing risperidone was based on concern about the shortand long-term side effects of haloperidol (Campbell et al. 1997 ) and emerging pilot data from several centers showing encouraging results with risperidone (see McDougle et al. 2000 for a detailed review). This article describes the methodological issues encountered and the design decisions taken in developing the multisite clinical trial of risperidone by the RUPP Autism Network.
Short-Term Safety and Efficacy
The primary purpose of the first phase of the study was to compare the short-term safety and efficacy of risperidone and placebo in the treatment of children and adolescents with autistic disorder. We hypothesized that risperidone would be more effective than placebo in reducing impulsive aggression, tantrums, SIB, screaming, and out-of-control behavior associated with autistic disorder. Important exploratory questions of interest included whether risperidone (a) would be more effective than placebo for improving repetitive behavior in children and adolescents with autistic disorder; (b) would be associated with extrapyramidal side effects; (c) would be associated with specific side effects such as excessive weight gain or prolactinemia; and (d) whether specific CYP450 2D6 genotypes would be associated with clinical response, a range of adverse effects, and/or higher steady-state levels of risperidone.
Placebo control
The rationale for placebo control was based on the intent to evaluate safety and efficacy. First, placebo response has been observed in serious disorders such as autism (Sandler et al. 1999) . Second, the only medication that could be proposed as a standard treatment for aggression and SIB in children with autistic disorder is haloperidol (Anderson et al. 1989 ). However, clinicians and families often avoid using this medication due to legitimate concerns about shortand long-term side effects (Campbell et al. 1977; McDougle et al. 2000) . A direct comparison of risperidone or haloperidol was discarded as clinically unacceptable. Behavior modification treatment was not considered a reasonable comparison either, because it is often tried before pharmacotherapy and it would be difficult to ensure blinding in the study. In the absence of a satisfactory standard treatment, therefore, placebo control was fully justified.
Placebo control was also justified because autism is a chronic condition, and treatment of associated behavioral symptoms often requires pharmacotherapy for long periods of time. It is therefore important to provide clear-cut evidence of medication efficacy and safety in order to validate extended use. A placebo-controlled trial is the most efficient method of testing treatment effects. Moreover, the placebo control group provides a contrast group for assessment of adverse events. The decision to conduct an 8-week trial was a compromise between the amount of time required to show a treatment effect and our interest in avoiding a prolonged period without active treatment for subjects randomly assigned to placebo. To minimize the potential burden of placebo assignment, subjects who were randomized to placebo and failed to show a clinically meaningful response (placebo nonresponders) were eligible to participate in an 8-week openlabel trial of risperidone after a minimum of 4 weeks in the double-blind phase (see Fig. 1 ). The 8-week, open-label trial mimicked the double-blind treatment with respect to dose schedule, frequency of follow-up visits, and outcome measurement. Tables 1 and 2 present the inclusion and exclusion criteria used in the study. Selection of these criteria was guided by the goal of producing generalizable results. For example, 25% to 33% of children with autism also have seizures (Cohen and Volkmar 1997) . If risperidone proves to be safe and effective in autism, children on anticonvulsants are likely to be treated with risperidone. Failure to include subjects on anticonvulsants would have limited the clinical application of the study findings. On the other hand, changes in anticonvulsant dose during the study could have had an impact on the child's behavior and/or the interpretation of adverse effects. Thus, this entry criterion was qualified by insisting that both the dose of medication and the seizure disorder were stable prior to entry.
Sample selection
The decision to include only subjects diagnosed with autism was based on the presumed greater variability in response if a wider range of PDD subjects was included in the study. Although autism is unlikely to be a homogeneous disorder, the inclusion of children with other forms of PDD in the study invited undue heterogeneity. Within the diagnostic category of autism, however, we attempted to maximize generalizability by including subjects across a wide range of IQ. Children below a mental age of 18 months were excluded because of the fundamental problem of making the diagnosis of autistic disorder in profoundly retarded children (Lord et al. 1994) .
The decision to include only children diagnosed with autistic disorder had two important implications. First, the prevalence of autistic disorder is 5 to 20 cases per 10,000 compared to 10 to 40 cases per 10,000 for other forms of PDD (Fombonne 1999; Chakrabarti and Fombonne 2001) . Thus, restricting study participation to subjects with autism accompanied by severe behavioral dyscontrol reduced the pool of eligible subjects. Second, although each site had investigators with expertise in the assessment and treatment of autism, the decision to include subjects with autism required a network-wide training on the administration of the Autism Diagnostic Interview-Revised to ensure reliability in the diagnosis.
Randomization and dose schedule
To make certain that treatment groups would be comparable, the randomization was balanced within site by pubertal status (Tanner stages I and II for prepubertal status and Tanner III or higher for postpubertal status), gender, and anticonvulsant use. The medication schedule was based on the subject's weight. Children weighing at least 20 kg at study entry were started at a dose of 0.5 mg at bedtime. As shown in Table 3 (top half), the dose was increased to 0.5 mg twice daily at day 4 and gradually thereafter to a maximum of 2.5 mg per day (1.0 mg in the morning and 1.5 mg at bedtime) by day 29. A similar but slightly faster dose schedule was used for children weighing 45 kg or more (maximum of 1.5 mg in the morning and 2.0 mg at bedtime) as is shown in Table 3 (bottom half). For children with baseline weight between 15 and 20 kg, the starting dose was 0.25 mg/day.  Males and females between the ages of 5 years and 17 years 2 months  DSM-IV diagnosis of autistic disorder (established by clinical assessment, corroborated by the Autism Diagnostic Interview)  Inpatients or outpatients  Medication free for at least 2 weeks for all psychotropic medications (4 weeks for fluoxetine or depot neuroleptics)  Anticonvulsants used for the treatment of a seizure disorder were permitted if the dosage had been stable for 4 weeks and the patient had been seizure free for at least 6 months.  Clinical Global Impressions severity score of at least 4 (moderately ill) at baseline rated by the blinded rater  A score of 18 or greater on the Irritability subscale of the Aberrant Behavior Checklist at baseline (on the parent-rated and/or clinician-rated version)  A mental age of at least 18 months as measured by the age-appropriate form of the Wechsler Intelligence Test, by the revised Leiter, or by the Mullen In all cases, the dose schedule was not fixed. The decision to increase the dose above 1 mg/day was based on clinical judgment. For example, in the presence of a positive clinical response as evidenced by a rating of much improved or very much improved on the Global Improvement item of the Clinician's Global Impressions (CGI) scale or clinically important side effects (e.g., sedation), the dosage was not automatically increased. If a symptomatic deterioration was evident at a subsequent visit, or if the dose-limiting side effect resolved, the clinical team was free to resume upward dose adjustment. In the double-blind trial, there were no dose increases allowed after day 29. After day 29, the dose was maintained until the endpoint (day 56), unless adverse effects emerged at which point the primary clinician could lower the dose of the medication. Finally, the clinical team was permitted to prescribe benztropine to manage extrapyramidal symptoms. Compliance.
Parents were given a diary card at each visit with day-by-day instructions about the medication dose. Compliance was monitored by pill counts and by review of the diary card at each visit. Any deviation from the prescribed dose was discussed in order to ensure an optimal dosing strategy. If the compliance fell below 70% of the prescribed dosage for a given week via pill count, parents were educated about the importance of taking the medication as prescribed. Continued deviation from the prescribed dosing regimen, in the absence of extenuating circumstances, would lead to the subject's termination from the study. Due to the predictable difficulties of drawing blood samples from this nonverbal, often aggressive population, we did not include the measurement of plasma drug level determinations as an additional method of discerning compliance during the study. The drug level drawn at endpoint, which was coincident with blood sampling for laboratory tests, permitted a check on compliance and an examination of the relationship between CYP 2D6 genotype, blood level, and clinical response.
Ensuring blindness and breaking the blind
The blind in a placebo-controlled study may be compromised by the emergence of obvious side effects. Therefore, each subject was followed by two clinicians: a blinded clinical evaluator, who focused on clinical ratings, and a blinded primary clinician, who evaluated side effects and adjusted the medication dosage. At the end of the double-blind phase, but before the treatment code was broken, each subject was classified as a responder or nonresponder. Positive treatment response was defined by a decrease of 25% on the Irritability subscale of the Aberrant Behavior Checklist and a rating of much improved or very much improved on the Global Improvement item on the CGI at endpoint. Once this determination was made, the primary clinician broke the treatment code and initiated the next step in the subject's treatment. The rationale for breaking the blind was to ensure continuity of care for subjects who benefited from the active medication during the double-blind phase and to evaluate subsequent clinical response to open-label treatment for placebo nonresponders in the double-blind phase.
At the end of the double-blind phase, subjects were cross-classified by treatment assignment and clinical response (risperidone responder, risperidone nonresponder, placebo nonresponder, or placebo responder). Risperidone responders were invited to participate in the 4-month extension study (Fig. 1) . These subjects were seen monthly for 4 months (see description of phase 2 below). Although visits were scheduled on a monthly basis, interim visits with the primary clinician were scheduled on an as needed basis.
Placebo nonresponders entered an 8-week, open-label risperidone trial, which mimicked the double-blind study with respect to weekly visits and dose schedule. These subjects were seen weekly for the first 4 weeks by the primary clinician to monitor side effects and adjust the dosage. The blinded clinical evaluator did not resume clinical ratings until the end of the first month in the open-label phase. This plan ensured continuity in that the same blinded clinical evaluator conducted outcome measures. It also provided some additional protection of the blind in that the blinded clinical evaluator remained unaware of treatment assignment during the double-blind study. Subjects who were judged to be responders after 8 weeks of open-label treatment were invited to enroll in the 4-month extension (phase 2) followed by the placebocontrolled discontinuation phase.
Risperidone nonresponders were treated in accordance with the best judgment of the clinical team and the family's preference. Similarly, responders to placebo in the double-blind phase were not invited into the 8-week open-label study (Fig. 1 ). These subjects were followed by the clinical team, and treatment decisions were based on the subject's clinical picture.
Data analytic plan for primary hypothesis in phase 1
Sample size.
The sample size of 100 was chosen to ensure sufficient power to detect a moderate treatment difference between risperidone and placebo. Based on conservative estimates, such as a positive response of 40% for the risperidone group and 10% for the placebo group, the power to detect a difference between treatments is 94% with 50 in each group. Even if the difference in the rate of positive response is only 25%, the power to detect that difference between groups would be 86% at the conventional 5% level of significance (Borenstein et al. 1997 ). The sample size of 100 was also intended to identify differences in the frequency of common adverse events across the two treatments. Adverse events with an expected frequency of 6% or larger are detectable with the projected sample size of 50 in each group with a power of 95%, whereas a frequency of 3% or larger is detectable with a power of 78%.
Evaluation of efficacy.
The intent-to-treat principle in which all randomized subjects are included in the analyses will guide the evaluation of efficacy (Fleiss 1986) . The primary outcome measure, the Irritability subscale of the Aberrant Behavior Checklist (completed by the parent), will be analyzed with a mixed effects linear model, also called a random regression model (Gibbons et al. 1993) . In this approach, each subject's response during the trial is modeled by regressing the response against time. The intercept and slope of the regression are estimated for each subject. A subject who shows a strongly positive response over time will have a much larger regression slope than a subject who barely changes over time. The average slope of the regression of response on time is compared across the risperidone and placebo groups and tested for statistical significance. An obvious advantage of the mixed model is that it permits a careful look at individual responses as well as group effects.
Another advantage of the mixed model is that it is more tolerant of missing data than repeated-measures analysis of variance, which only uses those subjects who have complete data. Analyses of data from only those subjects who complete the protocol may be biased by factors related to attrition. By contrast, subjects who terminate the protocol prematurely can be included in the mixed model. The random regression model can estimate change parameters as long as there are at least two observations over time.
A more straightforward and clinically relevant approach to evaluating the efficacy of risperidone is to calculate the difference in the rate of positive response between the two treatment groups. By using the definition of positive response described above, we will also compare the rate of positive response in each treatment group by a chi-square test. This computation will provide clinicians with an estimate of how likely a patient with similar problems will respond to treatment with risperidone.
Evaluation of safety.
Adverse events were systematically assessed and recorded at each visit by the primary clinician. Height, weight, vital signs, and concomitant medications were also documented at each weekly visit. An electrocardiogram and routine laboratory studies were conducted at the baseline and final visit in the double-blind phase (Kumra et al. 1997 ). Because our interest was in documenting any changes in cardiac conduction, electrocardiograms were read by pediatric cardiologists at all sites. Laboratory measures included complete blood count, electrolytes, blood urea nitrogen, creatinine, liver function tests, and urinalysis. Electroencephalograms were not done.
Differences in rates of adverse events between the risperidone and placebo groups will be tested by chi-square with Fisher's exact test when cell sizes are less than 5. Other analytic approaches will compare counts of adverse events in each of the two treatment groups using t tests.
Cytochrome P450 2D6 (CYP2D6) enzyme genotype and clinical response.
Risperidone is well absorbed orally and has an estimated 4-hour half-life in adults. The major metabolic pathway is oxidation via the CYP2D6 pathway (Heykants et al. 1994) . The major metabolite, 9-hydroxyrisperidone, appears to be equally potent as risperidone with respect to receptor binding activity. However, it has a 17-hour half-life and is not dependent on CYP2D6.
Recent studies indicate that 5% to 10% of the Caucasian population and 2% to 6% of the African American population have little or no activity of the CYP2D6 enzyme (He et al. 1999; Poolsup et al. 2000) . This lack of CYP2D6 activity is inherited as an autosomal recessive trait (homozygous for the low activity allele). By contrast, a small percentage of the population are ultrarapid metabolizers of CYP2D6 substrates due to gene amplification of the normal allele. To date, no studies have examined the relationship of CYP2D6 genotypes to risperidone level or clinical response in children and adolescents. By design, the dose of risperidone in children and adolescents in this study was constrained to fall in a narrow range (roughly 1.5 mg to 3.5 mg per day in divided doses). Despite this narrow range, we plan to evaluate the relationship between serum drug level, clinical response, and 2D6 genotype. The first set of exploratory analyses will examine the correlation of 2D6 genotype and blood level (adjusted for oral dose and body weight).
Given that 9-hydroxyrisperidone is not dependent on CYP2D6, individuals with low activity of CYP2D6 are likely to show a higher ratio of the parent compound to the active metabolite. Nonetheless, the combined level may be similar at equivalent doses. This ratio of parent compound to metabolite may be associated with different clinical responses. If true, this could have important clinical implications. We predict that the genotypes associated with little or no activity of the CYP2D6 enzyme will show the highest drug level of the parent compound (corrected for mg/kg). Additional exploratory analyses will include whether the trough level of the parent compound, the active metabolite, or the combination are associated with positive response or specific side effects such as sedation and/or weight gain.
Four-Month Extension Study
Several recent reviews have noted the limits of current knowledge regarding the impact of long-term drug exposure on the developing brain (Vitiello 1998 ) and the paucity of data on the effectiveness of pharmacotherapy in children beyond short-term trials (Vitiello and Jensen 1997) .
Results from recent case-control studies with risperidone suggest that adverse effects, such as weight gain, may not be evident in a short-term course of treatment (Kelly et al. 1998; . Thus, the primary aims of the 4-month extension phase were to determine whether the therapeutic gains achieved in the short term were stable and whether adverse effects emerged or intensified over time. To meet these goals, children and adolescents classified as responders to risperidone in phase 1 (the double-blind phase or the 8-week open-label study for the placebo nonresponders) were invited to participate in the 4-month, open-label extension phase. The prospective design of the extension protocol permitted evaluation of both continued benefit and the emergence of new side effects in a systematic fashion. If risperidone demonstrated superiority to placebo in the short term as well as enduring benefit over the additional 4-month observation period without the emergence of clinically meaningful adverse effects, it would be an important addition to the available treatments of children and adolescents with autism and related disorders.
Double-Blind Placebo-Controlled Withdrawal
Subjects who showed a positive response to risperidone through the 4-month extension phase were randomly assigned to continue active medication at the same maintenance dose or to gradual withdrawal to placebo over a 3-week period. The rate of medication withdrawal was roughly 25% per week. The maximum observation period in this final phase of the study was 8 weeks. Because withdrawal from active medication could result in relapse prior to the end of the planned observation, this design decision raised an important ethical concern that had to be balanced with scientific and clinical considerations.
First, we had to define relapse. Specific criteria for relapse were enumerated such that the return of target symptoms constituted treatment failure and marked the end of the discontinuation phase for that subject. Treating relapse as a discrete event permitted the use of clinically relevant statistical techniques that evaluate both the rate and time to relapse in each treatment group (see Analytic section below). This design feature also ensured that the placebo-controlled withdrawal period would not be prolonged to the full 8 weeks in the case of symptomatic relapse. Using the scores at randomization into the blinded discontinuation trial as baseline, relapse was defined as follows: a 25% or greater increase on the Irritability subscale of the Aberrant Behavior Checklist and two consecutive ratings by the blinded clinical evaluator of much worse or very much worse on the Global Improvement item of the CGI.
Second, although risperidone appears to have a better side effect profile than halperidol, the types and severity of adverse effects in children and adolescents have not been well documented. Moreover, virtually nothing is known about withdrawal effects such as dyskinesias, which have been shown to be common with haloperidol (Campbell et al. 1997 ). Thus, it was important to determine whether such withdrawal effects would also be present after treatment with risperidone. Given the chronic nature of autism and related disorders, this information should assist clinicians and families in making informed decisions about the risks and benefits of risperidone treatment. If subjects randomized to placebo substitution manifested relapse without emergence of dyskinesias, this would provide further evidence for the effectiveness of risperidone in this population.
Third, although autism is a chronic disorder, the symptom picture may change. New patterns of behavior may emerge over time. Thus, relapse was not a certainty. If subjects randomized to placebo substitution showed a return of target symptoms, long-term treatment with risperidone may be justified. On the other hand, if relapse did not occur, this would suggest that patients need not be exposed to a potent pharmacological agent beyond 6 months of treatment.
Fourth, drug withdrawal is common in clinical practice. Even in serious disorders such as autism, parents and/or clinicians may wonder if the target symptoms that prompted drug treatment are still present and often elect to discontinue the drug. Thus, the placebo-controlled withdrawal phase mimics clinical practice. A potentially important difference between clinical practice and the placebo-controlled withdrawal study is that subjects were carefully monitored during the withdrawal, providing the opportunity to produce generalizable data about withdrawal effects.
Fifth, if the target symptoms did return in the placebo substitution phase, we presumed that symptomatic control could be recaptured upon reinitiating active treatment. Furthermore, there is no evidence that, if relapse occurs in the short term during placebo substitution, the course of autism will be altered or worsened in the long term.
Analytic plan and stopping rule for placebo discontinuation phase
Relapse is the event of primary interest. Thus, the primary analytic strategy is to compare the rate of relapse in each group using a chi-square statistic (Fleiss 1986 ). Time to relapse will be evaluated for the risperidone and placebo groups by using Kaplan-Meier survival curves (logrank test). Other planned secondary analyses include the other subscales of the Aberrant Behavior Checklist, the Simpson-Angus scale, and the Abnormal Involuntary Movement Scale. Differences between the risperidone and placebo groups can be evaluated using standard linear statistical models.
In addition to the stopping rule for individual subjects who relapsed, we also developed a stopping rule for the entire discontinuation phase of the study. The stopping rule for this phase of the study was based on a simple statistical test: if the rate of relapse in the placebo group versus the active treatment group reached significance (defined as power of 80% and p < 0.01) in the planned interim analyses, the discontinuation phase of the study would be stopped. These interim analyses were planned when the sample size reached 16 (8 per group) and 32 (16 per group)-roughly equivalent to one third and two thirds of the expected total sample, respectively. Table 4 presents a range of values comparing the proportion of relapse across sample sizes.
Use of concomitant medications
To be eligible for the study, subjects had to be free of psychotropic medication for at least 2 weeks (4 weeks in the case of depot neuroleptics or fluoxetine). Anticonvulsant medications used for seizure control were permitted if the dose had been stable for 1 month and the subject had been seizure free for 6 months. We also needed a policy to manage subjects on stable doses of nonpsychotropic medication prior to entry. Moreover, given the long-term nature of the study, the likelihood that study participants would need concomitant medications for routine intercurrent illness or recrudescence of mild chronic conditions was predictably high. Concomitant medications taken during the study could have pharmacokinetic interaction with risperidone (e.g., absorption or hepatic metabolism) and/or pharmacodynamic interaction (e.g., effects on central dopaminergic systems). Thus, when describing the purpose and design of the study to subjects and their families, investigators emphasized the importance of reviewing all ongoing or proposed medication with the research team.
To guide the use of concomitant medications during the study, we classified common pediatric medications as acceptable, drugs to avoid, and drugs considered unacceptable. The rationale for these recommendations was to prevent drug interactions that might pose a safety hazard, cause additive side effects, or confound the interpretation of behavioral response to the study medication. For example, because erythromycin or ceterazine can increase the QT interval (although presumably rare, this has also been reported for risperidone), these drugs were classified as unacceptable. Antihistamines, which may have sedative side effects, and metoclopromide, which may cause akathisia, were also considered unacceptable. The decongestant, pseudoephedrine, which may produce hyperactivity in some children, was classified as a medication to avoid. Also considered were drugs that may have an impact on risperidone concentration (e.g., tetracycline may induce CYP 2D6, which presumably would lower risperidone level). These recommendations were organized into a list for investigators and a list for families. These lists were not exhaustive, but they contained specific recommendations about common medications, including over-the-counter remedies. Investigators were encouraged to consult with the subject's pediatrician about medications that were not on the list. Medication questions were also reviewed on the weekly investigator conference calls. (Copies of the Concomitant Medication guide for investigators and the handout for parents are available upon request to Larry Scahill.)
